Targeting the AHR–IDO1–kynurenine pathway in TREM2+ macrophages restores antitumor immunity in thyroid cancer - Top-Institutions - MDSpire

Modulating the AHR–IDO1–kynurenine axis in TREM2+ macrophages enhances antitumor immune responses in thyroid carcinoma

  • By

  • Fei Le

  • Xianming Huang

  • Youfang Jiang

  • Saiping Lv

  • Yaoyao Chen

  • July 21, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Immunology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Immunotherapy

  • #3

    Moffitt Cancer Center
    Moffitt Cancer Center

    Tampa, Florida

    Key Differentiators

    • Oncology
    • Cancer Research

  • #4

    The Ohio State University
    The Ohio State University

    Columbus, Ohio

    Key Differentiators

    • Oncology
    • Cancer Research

  • #5

    University of New Mexico Comprehensive Cancer Center
    University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico

    Key Differentiators

    • Oncology
    • Cancer Research

Original Source(s)

Targeting the AHR–IDO1–kynurenine pathway in TREM2+ macrophages restores antitumor immunity in thyroid cancer

  • by Fei Le, Xianming Huang, Youfang Jiang, Saiping Lv, Yaoyao Chen

  • July 21, 2026

Related Content

Rapid metastatic progression of primary pulmonary synovial sarcoma despite guideline-concordant multimodal therapy: a case report

Lipid metabolic plasticity in glioblastoma: mechanisms, tumor microenvironment remodeling, and therapeutic opportunities

Inflammatory myofibroblastic tumour: unravelling the interplay of inflammation, kinase signalling, and therapeutic resistance